Yamada S, Matsuoka Y, Kimura R
Department of Biopharmacy, School of Pharmaceutical Sciences, University of Shizuoka, Japan.
Pharm Res. 1993 Sep;10(9):1346-9. doi: 10.1023/a:1018982116273.
The relationship between the plasma concentration of mepirodipine (1,4-dihydropyridine Ca2+ antagonist) and its occupancy of cardiac and cerebral Ca2+ antagonist receptors in rats has been characterized by a radioreceptor assay technique using (+)-[3H]PN 200-110. Oral administration of mepirodipine in rats produced a dose-dependent and sustained decrease in the number of specific (+)-[3H]PN 200-110 binding sites in both tissues, and the effect was more pronounced in the cardiac tissue than in the cerebral cortex. The occupancy of cardiac and cerebral Ca2+ antagonist receptors by mepirodipine correlated well with its plasma concentration, whereas a 20-fold higher plasma concentration of this drug was necessary to occupy Ca2+ antagonist receptors in the cerebral cortex. Thus, these data suggest that mepirodipine occupies Ca2+ antagonist receptors in cardiovascular tissue selectively over those in brain tissue.
采用放射性受体分析技术,使用(+)-[³H]PN 200-110对大鼠体内甲哌地平(一种1,4-二氢吡啶类钙离子拮抗剂)的血浆浓度与其对心脏和大脑钙离子拮抗剂受体的占有率之间的关系进行了表征。大鼠口服甲哌地平后,两种组织中特异性(+)-[³H]PN 200-110结合位点的数量均出现剂量依赖性且持续下降,且该作用在心脏组织中比在大脑皮层中更为明显。甲哌地平对心脏和大脑钙离子拮抗剂受体的占有率与其血浆浓度密切相关,然而,该药物在大脑皮层中占据钙离子拮抗剂受体所需的血浆浓度要高出20倍。因此,这些数据表明,甲哌地平在心血管组织中对钙离子拮抗剂受体的占据选择性高于脑组织。